Monoclonal Antibodies for COVID-19
New Avenues to Pre-Exposure Prophylaxis
Clinical Practice Guidelines
COVID-19 Treatment Guidelines.
National Institutes of Health (NIH)
Clinician Resources
Federal response to COVID-19: monoclonal antibody clinical implementation guide.
Department of Health and Human Services (DHHS).
Talking with patients about monoclonal antibodies for COVID-19: tips and frequently asked questions.
DHHS.
Fact Sheet for Healthcare Providers: Emergency Use Authorization for bebtelovimab.
US Food and Drug Administration (FDA).
Fact Sheet for Healthcare Providers: Emergency Use Authorization of EVUSHELD™ (tixagevimab/cilgavimab).
FDA.
Fact Sheet for Healthcare Providers: Emergency Use Authorization of sotrovimab.
FDA.
OpenData Portal.
NIH.
Suggested Readings
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Cameroni E, Bowen JE, Rosen LE, et al. Nature. 2022;602(7898):664-670.
The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data.
Chodick G, Tene L, Rotem RS, et al. Clin Infect Dis. 2021;74(3):472-478.
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa.
Davies MA, Kassanjee R, Rosseau P, et al. medRxiv. 2022. [Epub ahead of print]
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2.
Di Fusco M, Moran MM, Cane A, et al. J Med Econ. 2021;24(1):1248-1260.
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients.
How J, Gallagher KME, Liu Y, et al. Leukemia. 2022:1-4.
At the heart of the matter: unmasking and addressing the toll of COVID-19 on diverse populations.
Haynes N, Cooper LA, Albert MA. Circulation. 2020;142(2):105-107.
Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients.
Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. N Engl J Med. 2021;385(7):661-662.
PROVENT: Phase 3 study of efficacy and safety of AZD7442 (tixagevimab/cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults.
Levin M, et al. IDWeek; September 29-October 3, 2021. Virtual conference.
AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans.
Loo Y-M, McTamney PM, Arends RH, et al. Sci Transl Med. 2022. [Epub ahead of print].
Data and clinical considerations for additional doses in immunocompromised people.
Oliver S. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention; July 22, 2021.
Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US.
Sun J, Zheng Q, Madhira V, et al. JAMA Intern Med. 2022;182(2):153-162.
Racial and ethnic disparities in receipt of medications for treatment of COVID-19—United States, March 2020-August 2021.
Wiltz JL, Feehan AK, Molinari NM, et al. MMWR Morb Mortal Wkly Rep. 2022;71(3):96-102.
Activity 1
Activity 3
Relevant Resources
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
A New Era in Precision Medicine
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
The PCPs Role in Preventing HIV
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
The PCP’s Role in Timely Recognition and Referral
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
Debates and Discussions About Personalizing Patient Management
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
From Guideline Recommendations to Daily Clinical Decision-Making
Hot Topics in HBV, HCV, and NASH
Improving Patient Outcomes Through Shared Clinical Decision Making
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
Digging Deep on Shared Decision-Making
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
Mechanistic Insights and Emerging Treatment Options
A PrEP Primer
A Foundation for Managed Care
A Focus on Exacerbation Prevention
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Unlocking Novel Paths to Patient Care
Maximizing Your Role to Impact Patient Outcomes
Evolving Best Practices for Patient Management
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
The Increasing Role of JAK Inhibitors
Shared Decision-making in the Era of Biologics
New Pathways to Patient Management
From Comprehensive Patient Evaluations to Individualized Evidence-based Care
Preventing COPD Exacerbations to Improve Outcomes
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Evolving Best Practices for Pediatric Patients
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
New Pathways to Optimize Patient Outcomes
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
Debates and Discussions About New Upstream Treatment Avenues
A Case-Based Update on Pediatric Patients
